Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Leflunomide in systemic lupus erythematosus].

Aharon Kessel, Elias Toubi

    Harefuah
    |May 23, 2002
    PubMed
    Summary

    Leflunomide, an antirheumatic drug, shows promise for treating systemic lupus erythematosus by inhibiting pyrimidine synthesis. This study details successful leflunomide treatment in two lupus patients, supporting its potential therapeutic role.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Real-World Variation in Post-Dose Supervision and Activity Restriction During Maintenance Cow's Milk Oral Immunotherapy.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
    Same author

    Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.

    The World Allergy Organization journal·2026
    Same author

    [Primary Prevention of Food Allergies - Is It Feasible?]

    Harefuah·2026
    Same author

    The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities.

    The World Allergy Organization journal·2026
    Same author

    Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

    The Lancet. Haematology·2026
    Same author

    [Eosinophilic Gastrointestinal Diseases: Diving beyond the Tip of the Iceberg].

    Harefuah·2026

    Area of Science:

    • Immunology
    • Rheumatology
    • Pharmacology

    Background:

    • Leflunomide is an established antirheumatic drug.
    • Its mechanism involves inhibiting de novo pyrimidine ribonucleotide biosynthesis.
    • It is approved for Rheumatoid Arthritis treatment.

    Observation:

    • Pilot studies suggest leflunomide may benefit systemic lupus erythematosus (SLE) patients.
    • This report presents two cases of successful leflunomide treatment in SLE.
    • Literature review on leflunomide in SLE is included.

    Findings:

    • Successful treatment outcomes were observed in two SLE patients using leflunomide.
    • Leflunomide's efficacy in SLE warrants further investigation.
    • The drug's mechanism may be relevant to SLE pathogenesis.

    Implications:

    • Leflunomide could be a viable treatment option for systemic lupus erythematosus.
    • Further clinical trials are needed to confirm leflunomide's efficacy and safety in SLE.
    • Understanding leflunomide's role in pyrimidine biosynthesis may offer new therapeutic strategies for autoimmune diseases.

    Related Experiment Videos